Caribou Biosciences (CRBU) Cash from Investing Activities (2020 - 2026)

Caribou Biosciences (CRBU) has reported Cash from Investing Activities for 7 consecutive years, with $24.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 51.43% year-over-year to $24.0 million; the TTM figure through Mar 2026 stood at $76.8 million (down 32.02% YoY), while the FY2025 annual figure was $102.2 million, up 18.05% from the prior year.
• Cash from Investing Activities grew to $24.0 million in Q1 2026 per CRBU's latest filing, from $18.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $49.4 million in Q1 2025 and bottomed at -$72.1 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged $3.0 million across 5 years, with a median of $15.9 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 327659.09% — and 2023, when it jumped 179.18%.
• Caribou Biosciences' Cash from Investing Activities stood at $1.2 million in 2022, then tumbled by 2790.09% to -$31.5 million in 2023, then surged by 150.61% to $15.9 million in 2024, then increased by 12.81% to $18.0 million in 2025, then soared by 33.47% to $24.0 million in 2026.
• Business Quant data shows CRBU's Cash from Investing Activities at $24.0 million in Q1 2026, $18.0 million in Q4 2025, and $10.9 million in Q3 2025.